openPR Logo
Press release

Glioma Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, and Future Outlook

08-26-2025 08:44 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Glioma Competitive Landscape & Pipeline 2025: Emerging

DelveInsight's, "Glioma Competitive landscape, 2025," report provides comprehensive insights about 200+ companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the full insights into the evolving Glioma Pipeline and discover which companies are leading the innovation race @ Glioma Competitive Landscape Report [https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Glioma Competitive Landscape Report

* On 19 August 2025, Nuvation Bio Inc. announced a study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma.
* DelveInsight's Glioma Competitive Landsapereport depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies for Glioma treatment.
* The leading Glioma Companies such as Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac , and others.
* Promising Glioma Therapies such as DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide , and others.

Unlock detailed analysis of the Glioma Competitive Landscape 2025 and identify key growth opportunities @ Glioma Research and Development Report [https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glioma Marketed Therapies

* Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, the innovative science and digital technologies to create transformative treatments in areas of great medical need and find new medicines, the company consistently rank among the world's top companies investing in research and development.

* Tafinlar + Mekinist

The combination of Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition research and patients reached, helps in slowing tumor growth by blocking signals associated with the BRAF and MEK kinases that are implicated in the growth of various types of cancer. Tafinlar + Mekinist has been studied in more than 6,000 BRAF-positive patients in more than 20 ongoing and completed trials, including in pediatric patients 1 year of age and older, and has been prescribed to more than 200,000 patients worldwide.

* NX Development Corp.

NX Development Corp. (NXDC) is a life sciences company based in Lexington, KY dedicated to the development of ALA HCl for tumor visualization. NXDC is a wholly-owned subsidiary of photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; ""PHN""). PHN is the licensor of GleolanTM (aminolevulinic acid HCl [ALA HCl]) to NXDC. The companies share an eight-year working relationship and are wholly-owned by SBI Holdings Inc. (Tokyo, Japan).

* GLEOLAN

GLEOLAN (ALA HCl) is an FDA-approved optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. Exogenous administration of ALA HCl leads to accumulation of its metabolite protoporphyrin IX (PpIX) in tumor cells. Under an operating microscope adapted with a specific blue emitting light source and filters, tumor tissue is visualized as red fluorescence. Tissue lacking sufficient PpIX concentrations appears blue. Because of its unique mechanism-of-action, GLEOLAN may allow neurosurgeons to see malignant tissue during surgery under blue light that they may not see under standard white light.

Glioma Pipeline Therapies

* Bristol-Myers Squibb

The Bristol-Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

* Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response. By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. Opdivo's leading global development program is based on Bristol Myers Squibb's scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

* Orbus Therapeutics

Orbus Therapeutics Inc. is a late-stage, private biopharmaceutical company that is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company is focused and passionate about bringing a more positive outcome to patients facing life threatening or significantly life altering diseases.

* Eflornithine

Eflornithine, also known as a-diflurormethylornithine (DFMO), selectively targets and irreversibly inhibits ornithine decarboxylase (ODC), an enzyme essential for polyamine synthesis, and DNA and RNA function. Unlike multi-targeted tyrosine kinase inhibitors on the market or in development, eflornithine targets only one specific enzyme, ODC. In animal studies, eflornithine has been shown to inhibit the growth of malignant tumors, including intra cerebral mid- and high-grade gliomas. Eflornithine administration has also been shown to potentiate the anti-tumor activity of other chemotherapy agents. In single-arm and controlled, randomized clinical trials, eflornithine oral solution increased survival in patients with both newly diagnosed and recurrent anaplastic glioma. The primary and reversible side effects of eflornithine were diarrhea and hearing impairment.

* Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax Registered dendritic cell-based vaccines.

* DCVax-L

DCVax Registered is a platform technology that uses activated dendritic cells (the master cells of the immune system), and is designed to reinvigorate and educate the immune system to attack cancers. Unlike conventional cancer drugs, which use one active agent to hit one target on the cancer, DCVax uses many active agents to hit many targets on the cancer. For DCVax-L, the monocytes are differentiated into dendritic cells, and matured, activated and loaded with biomarkers ("antigens") from the patient's own tumor tissue (which is collected in a simple kit at the time of surgery to remove the tumor). The loading of biomarkers into the dendritic cells "educates" them about what the immune system needs to attack. The activated, educated dendritic cells are then isolated with very high purity and comprise the DCVax-L personalized vaccine. DCVax -L is administered to the patient through a simple intra-dermal injection in the upper arm, similar to a flu shot. The dendritic cells then convey the tumor biomarker information to the rest of the immune system agents (T cells, B cells and others), as "marching orders," and the immune system agents then fan out through the body searching for anything with these biomarkers and attacking it.

* Medicenna Therapeutics

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna's early-stage BiSKITs Trademark program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically "cold" tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer.

* MDNA55

MDNA55 is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2.

* Adastra Pharmaceuticals

Adastra Pharmaceuticals Inc. is an innovative, private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. The company's vision is to identify, develop and deliver to patients important new therapies for diseases with significant unmet need. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

* Zotiraciclib

Zotiraciclib (TG02) is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). Zotiraciclib has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of gliomas. As of January 2020, zotiraciclib is being evaluated by Adastra Pharmaceuticals in two separate Phase 1b clinical trials for the treatment of glioblastoma multiforme (GBM). Zotiracicib is also being developed as a potential treatment for diffuse intrinsic pontine glioma (DIPG), a rare pediatric cancer. Both forms of brain cancer are characterized by Myc overexpression. It is currently being investigated in Phase I/II clinical trial to treat patients with Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations.

* Onxeo

Onxeo is a French clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA-binding functions. The company's therapeutic strategy focuses on fighting tumor resistance to treatments which poses ever-greater therapeutic challenges, further more so in aggressive or rare cancers. The approach is based upon unique mechanisms of action on DNA Damage Response and immune response and focuses on bringing first-in-class and disruptive compounds from translational research to proof-of-concept in man in cancer indications with high unmet needs.

* AsiDNA

A first-in-class product candidate in the leading field of DNA Damage Response (DDR), AsiDNA disrupts and exhausts the ability of tumor cells to repair their DNA by acting upstream of multiple repair pathways. AsiDNA and its technology originate from three major French academic centers: Curie Institute, CNRS, and the Museum of Natural History. It aims to offer new treatment options for patients suffering from various types of cancer. AsiDNA is a short double-stranded DNA fragment (oligonucleotide) that acts as a decoy, mimicking double-strand breaks in the DNA of the tumor cell. AsiDNA molecules trigger false DNA break signals to activate and attract DNA repair proteins, which prevents their recruitment to the site of actual DNA damage. As a result, damages to tumor cells' DNA remain unrepaired.

Gain strategic intelligence on Glioma Emerging Therapies, pipeline highlights, and competitive trends shaping the Glioma market @ Glioma Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Glioma Analytical Perspective by DelveInsight

* In-depth Commercial Assessment: Glioma Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Glioma Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Glioma Competitive Landscape Report Assessment

* Company Analysis
* Therapeutic Assessment
* Pipeline Assessment
* Inactive drugs assessment
* Unmet Needs

Stay informed on the latest advancements in Glioma Research and development-Download the in-depth pipeline and competitive landscape report @ Glioma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Glioma Competitive Landscape Report

* Coverage- Global
* Glioma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Sanofi, Merck Sharp & Dohme LLC, Oblato Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals, Ever Supreme Bio Technology, Chia Tai Tianqing Pharmaceutical Group, CytoVac , and others.
* Glioma Therapies- DS-1001b, Radiotherapy, Nimotuzumab, AP23573, Nimotuzumab, BLZ-100, LY2157299, Temozolomide , and others.
* Glioma Marketed Therapies and Pipeline Therapies
* Glioma Preclinical and Discovery Stage Products, Unmet Needs

Understand the Glioma Companies, drugs, and market dynamics driving the Glioma Pipeline in 2025-Request your copy of the report now @ Glioma Mechanism of Action and Unmet Needs [https://www.delveinsight.com/sample-request/glioma-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Glioma: Overview
* Glioma -Analytical Perspective: In-depth Commercial Assessment
* Competitive Landscape
* Therapeutic Assessment
* Glioma: Company and Product Profiles (Marketed Therapies)
* Novartis
* Tafinlar + Mekinist
* Glioma: Company and Product Profiles (Pipeline Therapies)
* Late Stage Products (Phase III)
* Bristol-Myers Squibb
* Opdivo
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Medicenna Therapeutics
* MDNA55
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Onxeo
* AsiDNA
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Evgen Pharma
* SFX-01
* Drug profiles in the detailed report.....
* Inactive Products
* Glioma Unmet needs
* Glioma Market drivers and barriers
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioma-competitive-landscape-pipeline-2025-emerging-therapies-leading-companies-and-future-outlook]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glioma-competitive-landscape

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glioma Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading Companies, and Future Outlook here

News-ID: 4160481 • Views:

More Releases from ABNewswire

Hypothalamic Obesity Market: Epidemiology, Pipeline Therapies, and Leading Companies | DelveInsight | Rhythm Pharmaceuticals and Others
Hypothalamic Obesity Market: Epidemiology, Pipeline Therapies, and Leading Compa …
The hypothalamic obesity market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM hypothalamic obesity market size from 2020 to 2034. The report also covers current hypothalamic obesity treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential. Emerging therapies for Hypothalamic Obesity, including LB54640 and others, are anticipated to drive significant growth in the
Lennox Gastaut Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Takeda, Marinus Pharmaceuticals, SK biopharmaceuticals, CuroNZ, TAHO Pharmaceutic
Lennox Gastaut Syndrome Clinical Trials, Companies, Therapeutic Assessment, Ther …
DelveInsight's, "Lennox-Gastaut Syndrome - Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lennox-Gastaut Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. DelveInsight reports that over 10 key companies are actively developing
Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Sanofi, Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials, Companies, Th …
DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025" report provides comprehensive insights about 2+ companies and 4+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP)pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. DelveInsight reports that more than two key companies are actively developing over four therapeutic candidates for
Severe Asthma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Severe Asthma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Appr …
DelveInsight's, "Severe Asthma Pipeline Insight 2025" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Severe Asthma pipeline landscape. It covers the Severe Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Severe Asthma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Download DelveInsight's comprehensive Severe Asthma Pipeline

All 5 Releases


More Releases for Glioma

Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent advances
Glioma Competitive Landscape 2023 (Updated)
DelveInsight's, "Glioma Competitive Landscape 2023" report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioma Competitive Landscape Report • DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market. Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187 The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioma Pipeline Report • DelveInsight's glioma pipeline report depicts a
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there